Zimmer Biomet Holdings Inc
ZBH
ISIN null / Valor 1262932
Zimmer Biomet Holdings Inc
UMushroom community rating:
About company
Zimmer Biomet Holdings Inc is a global leader in musculoskeletal healthcare, providing a comprehensive range of products and services to help healthcare professionals treat patients suffering from joint disorders and other orthopedic conditions. The company offers a wide variety of innovative solutions, including joint replacement implants, surgical tools, and biologics, to improve patient outcomes and enhance quality of life. With a strong focus on research and development, Zimmer Biomet is dedicated to advancing the field of orthopedics and delivering cutting-edge technologies to meet the evolving needs of healthcare providers and patients worldwide.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (26.10.2025):
In the second quarter of 2025, Zimmer Biomet Holdings Inc reported net sales of $2.077 billion, marking a 7.0% increase compared to the prior year. The company also saw a rise in diluted earnings per share and updated its full-year financial guidance, reflecting continued growth and strategic advancements.
Second Quarter Net Sales Growth
Zimmer Biomet Holdings Inc achieved net sales of $2.077 billion in Q2 2025, up 7.0% on a reported basis, 5.4% on a constant currency basis, and 2.8% on an organic constant currency basis, demonstrating robust market performance.
Increased Earnings Per Share
The company's diluted earnings per share for the second quarter were $0.77, while adjusted diluted earnings per share rose by 3.0% to $2.07, highlighting improved profitability.
Updated Financial Guidance
Zimmer Biomet tightened its full-year 2025 revenue growth guidance to between 6.7% and 7.7% on a reported basis, 6.2% to 7.2% on a constant currency basis, and 3.5% to 4.5% on an organic constant currency basis. Additionally, the company increased its adjusted earnings per share guidance to $8.10 - $8.30.
Strategic Acquisitions and Partnerships
The company announced the acquisition of Monogram Technologies to enhance its robotics suite and signed a strategic partnership with Getinge to distribute Operating Room capital products, reinforcing its commitment to innovation and expanding its global footprint.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
17727 M
Market cap (USD)
1,997,472
Daily traded volume (Shares)
106.22 / 104.7
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Federico Ferrari
EQUITIES OF THE SAME SECTOR
